Montelukast 5mg Tablet Franchise in Ahmedabad

Anti-Asthmatic & Allergy Therapy Supplier in Mumbai

Monclip 5 Tablet Distributor in Delhi

Asthma & Respiratory Relief Tablet Franchise Opportunity in Bangalore

Pediatric Allergy & Asthma Tablet Stockist in Hyderabad
Montelukast 5mg Export & Manufacturing in Chandigarh

Home/Products /montelukast-5mg-tablet

Monclip 5 Tablet

Composition : Montelukast (5mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*15

Price : ₹1/-

Monclip 5 Tablet contains Montelukast 5mg, a selective leukotriene receptor antagonist indicated for the management of asthma and allergic rhinitis. It helps reduce airway inflammation, prevent bronchoconstriction, and alleviate hypersensitivity reactions, supporting better respiratory health.

Montelukast works by blocking leukotriene receptors, preventing inflammatory mediators from narrowing airways. This action helps control asthma symptoms, reduces the frequency of attacks, and improves quality of life for patients with allergies.

For distributors and healthcare suppliers, Monclip 5 Tablet is a high-demand respiratory therapy product, widely recommended in pediatric, adult, and hospital care settings. The growing prevalence of asthma and allergic conditions ensures consistent year-round demand.

Adding Monclip 5 Tablet to your anti-asthmatic and allergy therapy segment creates strong opportunities in pharmacies, hospitals, pediatric clinics, export markets, and third-party manufacturing. Its proven efficacy, broad usability, and strong prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.

Read More

About the Product

Monclip 5 Tablet contains Montelukast 5mg, a selective leukotriene receptor antagonist indicated for the management of asthma and allergic rhinitis. It helps reduce airway inflammation, prevent bronchoconstriction, and alleviate hypersensitivity reactions, supporting better respiratory health.

Montelukast works by blocking leukotriene receptors, preventing inflammatory mediators from narrowing airways. This action helps control asthma symptoms, reduces the frequency of attacks, and improves quality of life for patients with allergies.

For distributors and healthcare suppliers, Monclip 5 Tablet is a high-demand respiratory therapy product, widely recommended in pediatric, adult, and hospital care settings. The growing prevalence of asthma and allergic conditions ensures consistent year-round demand.

Adding Monclip 5 Tablet to your anti-asthmatic and allergy therapy segment creates strong opportunities in pharmacies, hospitals, pediatric clinics, export markets, and third-party manufacturing. Its proven efficacy, broad usability, and strong prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.

Common side effects may include headache, abdominal pain, cough, or mild dizziness. Rare but serious side effects can include mood changes, agitation, or allergic reactions. Patients should consult their doctor if severe or persistent symptoms occur.

Monclip 4 Tablet is indicated for the prophylaxis and chronic treatment of asthma in children, prevention of exercise-induced bronchoconstriction, and management of seasonal or perennial allergic rhinitis.

Before taking Monclip 4 Tablet, inform your doctor about any liver disease, history of neuropsychiatric disorders, or allergy to Montelukast. The tablet should be taken once daily, preferably in the evening, and is not intended for relief of acute asthma attacks.

Store Monclip 4 Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and ensure the blister pack is intact. Do not use the tablet beyond its expiry date.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation